A bimatoprost sustained-release implant reduced IOP by approximately 30% over 12 weeks in a second phase 3 study, Allergan announced in a press release.
The majority of patients with open-angle glaucoma or ocular hypertension in the 528-subject trial were also able to remain treatment-free for at least 1 year after the last implant was inserted, the release said.
“The data results of intracameral Bimatoprost SR were consistently demonstrated in two pivotal trials, highlighting the sustained, predictable and potentially sight-saving benefits of this exciting new approach in treating
Uncategorized